NEW DELHI :
APEX drugs regulatory body
CDSCO has directed drug
Controllers of all States and
UnionTerritories to stop manufacture, sale and distribution of
unapproved 35 fixed-dose combination drugs that include
painkillers, nutrition supplements and anti-diabetics.
They have also been asked to
review their approvalprocess for
such fixed dose combination
drugs (FDC) and ensure strict
compliance of the provisions of
the Drugs and Cosmetics Act
1940 and rules.
FDC drugs are those which
contain a combination of two or
more active pharmaceutical
ingredients (APIs)in afixedratio.
The regulatorissued thedirections after it found that certain
FDC drugs have been licensed
for manufacture, sale, and distribution without prior evaluation of safety and efficacy, posinga serious risk topublichealth
and safety. In a communication
sentonApril11,DrugsController
Generalof India (DCGI)DrRajeev
Raghuvanshi referred to the letterissuedbyhisofficeon January
2013whereconcernswereraised
regarding the grant of manufacturing licenses for sale of FDC
drugs that fall under the definitionofa“NewDrug”in thecountry without due approval fromDCGI. The same concern hasbeenraised from time to timeandmultiplelettershavebeenissuedto the respective state licensingauthorities that granted permission formanufacturing andmarketing of unapproved FDCs.
Themost recent such letter wasissued in February this year.
“It has come to the notice of
this directorate that certain FDCdrugs have been licensed formanufacture, sale, and distribution without prior evaluation of
safetyand efficacyasper theprovisionofNDCTRules 2019underthe Drugs and Cosmetics Act
1940. This poses a serious risk topublichealth and safety,”theletter stated.
The approval of such unapproved FDCs compromisespatient safety and may lead to adverse drug reactions, druginteractions, and other healthhazardsdue to theabsenceofscientific validation, the letterunderlined. Upon issuance of
show cause notices to the manufacturers, they have stated that
these licenses were granted bythe respective drug licensingauthorities and have not violated any rules, it said.